Diligence memo · auto-generated · as of July 2, 2026
Gaingels Delix Therapeutics LLC
Gaingels Delix Therapeutics LLC looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Gaingels Delix Therapeutics LLC operates in Pharma, based in BURLINGTON.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Gaingels Delix Therapeutics LLC has raised $247K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $247K on 2021-11-03.
Most recent recorded round closed around 2021-11-03.
Valuation (modeled)modeled
Provath models Gaingels Delix Therapeutics LLC at approximately $5.3M (range $138K–$40M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.40× the median modeled value of Pre-Seed Pharma companies in 2019–2021 (20 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 4.7 yr ago; this sector typically re-raises about every 16 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 22% of Pharma peers (310 compared).
Modeled value ranks above 28% of those peers.
Closest niche peers: Jupiter Therapeutics, Inc., Tavros Therapeutics, Inc., Kalytera Therapeutics, Inc., Veterinary Radiation Oncology of the Chesapeake, LLC, Chamishi Therapeutics, Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.